title: Acute-phase treatment in general hospitals: clinical psychopharmacologic evaluation in first-episode schizophrenia patients.
abstract: A case-control study was conducted to investigate possible predictors of response to antipsychotic treatment in acute schizophrenic patients. During a 14-month period, 13 female first-episode schizophrenic patients were included. According to their antipsychotic treatment response 8 weeks after admission, they were placed in either a good-response group (n = 8) or poor-response group (n = 5). Scores of the two groups differed on several items of the Positive and Negative Syndrome Scale (PANSS) at baseline and during the following 8 weeks. At baseline, the maximum scores for Conceptual disorganization, Poor rapport, Passive/apathetic social withdrawal, and Stereotyped thinking in the good-response group were lower than the corresponding minimum scores in the poor-response group. Furthermore, minimum improvements after 1 week in scores for excitement in the good-response group were higher than the maximum improvements in the corresponding scores of the poor-response group. These PANSS items might serve as simple and rapid predictors of treatment resistance. In addition, Lack of judgment and insight significantly improved by 1 week, and further improved by 5 weeks in the good-response group. This suggests that treatment in the good-response group will be optimal if provided during a hospital stay of appropriate length.
authors.affiliation: Department of Psychiatry, Juntendo University School of Medicine, Hongo 2-1-1, Bunkyo-ku, 113-8421, Tokyo, Japan. khatta@med.juntendo.ac.jp
authors.forename: Kotaro
authors.initials: K
authors.lastname: Hatta
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Nakamura
authors.forename: Ichiyo
authors.initials: I
authors.lastname: Matsuzaki
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D005260:Female; D006760:Hospitalization; D006769:Hospitals, General; D006801:Humans; D007902:Length of Stay; D008297:Male; D008728:Methotrimeprazine / Q000627:therapeutic use*; D008875:Middle Aged; D018967:Risperidone / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy* / Q000534:rehabilitation*
chemical_list: D014150:Antipsychotic Agents; D008728:Methotrimeprazine; D018967:Risperidone